Nurix Therapeutics Files 8-K

Ticker: NRIX · Form: 8-K · Filed: Oct 22, 2025 · CIK: 1549595

Sentiment: neutral

Topics: 8-K, SEC Filing

Related Tickers: NRIX

TL;DR

Nurix filed an 8-K, but the details are missing in this snippet.

AI Summary

Nurix Therapeutics, Inc. filed an 8-K on October 22, 2025, reporting on other events and financial statements. The filing does not contain specific details about new agreements, material events, or financial figures within the provided text.

Why It Matters

This 8-K filing indicates that Nurix Therapeutics is providing updates to the SEC, which could contain material information for investors. However, the provided text lacks specific details on the nature of these updates.

Risk Assessment

Risk Level: low — The filing is a standard 8-K, and the provided text does not contain any specific negative or positive material events.

Key Players & Entities

FAQ

What specific events are being reported in this 8-K filing by Nurix Therapeutics?

The provided text indicates the filing is for 'Other Events' and 'Financial Statements and Exhibits' but does not specify the exact nature of these events or statements.

When was this 8-K filing submitted by Nurix Therapeutics?

The filing was submitted on October 22, 2025.

What is the principal business address of Nurix Therapeutics?

The principal executive offices are located at 1700 Owens Street, Suite 205, San Francisco, California 94158.

What is Nurix Therapeutics' IRS Employer Identification Number?

The IRS Employer Identification Number for Nurix Therapeutics is 27-0838048.

What is the SEC file number for Nurix Therapeutics?

The SEC file number for Nurix Therapeutics is 001-39398.

Filing Stats: 1,651 words · 7 min read · ~6 pages · Grade level 14.5 · Accepted 2025-10-22 09:04:11

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 22, 2025, Nurix Therapeutics, Inc. (the "Company") issued a press release announcing the initiation of the DAYBreak clinical trial, a pivotal single-arm Phase 2 study of bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In addition, on October 22, 2025, the Company updated its investor presentation. Copies of the press release and investor presentation are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. In addition, the information set forth under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K.

01 Other Events

Item 8.01 Other Events. On October 22, 2025, the Company announced the initiation of the DAYBreak clinical trial, a pivotal single-arm Phase 2 study of its Bruton tyrosine kinase ("BTK") degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma ("r/r CLL/SLL"). DAYBreak Phase 2 Study Design and Objectives The DAYBreak study will enroll approximately 100 patients with r/r CLL/SLL who have experienced disease progression following treatment with a covalent BTK inhibitor ("cBTKi"), a non-covalent BTK inhibitor ("ncBTKi") and a BCL-2 inhibitor ("BCL-2i"). The DAYBreak study aims to evaluate bexobrutideg's potential to address an unmet medical need in this patient population and generate data to support a potential Accelerated Approval submission. The DAYBreak study's primary efficacy endpoint is objective response rate per International Workshop on CLL ("iwCLL") criteria as assessed by an Independent Review Committee ("IRC"). The first DAYBreak study site was activated in October 2025. Dose Selection and Regulatory Alignment The DAYBreak study and the Company's planned Phase 3 confirmatory study of bexobrutideg will evaluate the 600 mg dose taken once daily ("QD"). The selection of the 600 mg dose follows the completion of analysis of data from a randomized cohort within the Phase 1b study comparing 200 mg and 600 mg in accordance with Project Optimus and reflects alignment with global regulators including the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency, and the European Medicines Agency. Planned Phase 3 Confirmatory Study The Company plans to initiate a randomized confirmatory Phase 3 trial of bexobrutideg in the first half of 2026 in r/r CLL/SLL patients whose disease progressed while receiving a cBTKi. This global Phase 3 confirmatory trial in patients treated in the second line or later setting will enroll approximately 400 patien

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release announcing initiation of clinical trial, dated October 22, 2025 99.2 Investor Presentation, dated October 22, 2025 104 Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document)

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the therapeutic potential of bexobrutideg, the Company's plans for the clinical development of bexobrutideg, the planned timing for the initiation and enrollment of patients in current and future clinical trials of bexobrutideg, the planned timing for the provision of updates and findings from the Company's clinical trials, the potential for accelerated approval, and the Company's ability to fund development activities and achieve development goals, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether the Company will be able to advance, obtain regulatory approval of and ultimately commercialize bexobrutideg, the timing and results of clinical trials, the Company's ability to fund development activities and achieve development goals, and other risks and uncertainties described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2025 and other SEC filings. The Company disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law. 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NURIX THERAPEUTICS, INC. Date: October 22, 2025 By: /s/ Christine Ring Christine Ring, Ph.D., J.D. Chief Legal Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing